The Board of Directors have approved the Standalone Unaudited Financial Results for the quarter ended on 30th June 2025.

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.8%Reaction day

₹303.20

prior close

₹292.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-7.0% vs market

Pharmaceuticals peers, median of 148sector+0.3%-7.2% vs sector

On the reaction day the stock moved 7.0 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+1.0

15m

+1.0

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.8+0.2-7.0+0.3-7.2

Next day

-7.6+0.2-7.8+0.3-7.9

-6.9+0.9-7.8+0.6-7.6

-8.6+0.1-8.7-0.3-8.3

-7.3+1.6-8.9+0.5-7.9

-3.0+2.8-5.9+0.6-3.6

-5.7+3.0-8.7+0.8-6.4

15d

+4.6+2.8+1.7+0.1+4.5

+17.1+3.1+14.0+1.3+15.7

+62.9+1.4+61.5-1.6+64.5

+54.2+1.4+52.8-4.4+58.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

BDH Industries' Board of Directors approved standalone unaudited financial results for Q1 FY26 (quarter ended 30 June 2025) at a meeting held on 8 August 2025. Revenue from operations rose to ₹1,862.42 lakhs from ₹1,625.82 lakhs in Q1 FY25, a growth of about 14.6% year-on-year. Profit after tax (PAT) increased to ₹182.66 lakhs from ₹156.85 lakhs, up roughly 16.4% YoY, with EPS of ₹3.17 versus ₹2.17. The Pharmaceutical segment remains the core business with ₹1,830.22 lakhs in revenue, while Renewable Energy contributed ₹32.20 lakhs. The statutory auditor CLB & Associates issued an unmodified (clean) limited review report with no qualifications or emphasis of matter.

Likely market impact

Steady double-digit growth in both revenue and profit with a clean audit opinion is a positive signal for shareholders, indicating stable operations. The modest scale of the company and reliance on the pharmaceutical segment remain key things for investors to watch.